At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,008 enrolled
Drug / intervention
Edoxabandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation (NVAF)
In Brief
An observational study evaluating Edoxaban for Atrial Fibrillation. Completed, enrolled 3,008 participants across 47 sites in 2 countries.
Detailed Summary
In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the Non valvular Atrial Fibrillation (NVAF) indication, Daiichi-Sankyo proposed this non-interventional study to gain insight into the safety (bleeding, liver adverse events, all-cause mortality and other drug related adverse events) and efficacy of edoxaban use in non-preselected patients with NVAF.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesSouth Korea, Taiwan
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartFeb 2017
Primary CompletionOct 2020
TodayJul 2026
First PostedNov 1, 2016
Enrollment StartFeb 21, 2017
Primary CompletionOct 15, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.7 years ago
Interventions
Edoxabandrug
Prescribed according to approved label